JP2013121353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013121353A5 JP2013121353A5 JP2013006880A JP2013006880A JP2013121353A5 JP 2013121353 A5 JP2013121353 A5 JP 2013121353A5 JP 2013006880 A JP2013006880 A JP 2013006880A JP 2013006880 A JP2013006880 A JP 2013006880A JP 2013121353 A5 JP2013121353 A5 JP 2013121353A5
- Authority
- JP
- Japan
- Prior art keywords
- binding site
- antibody
- amino acid
- domain
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 38
- 102000036639 antigens Human genes 0.000 claims 38
- 108091007433 antigens Proteins 0.000 claims 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229940127121 immunoconjugate Drugs 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 102000016359 Fibronectins Human genes 0.000 claims 3
- 108010067306 Fibronectins Proteins 0.000 claims 3
- 102000001708 Protein Isoforms Human genes 0.000 claims 3
- 108010029485 Protein Isoforms Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000000844 anti-bacterial effect Effects 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90958007P | 2007-04-02 | 2007-04-02 | |
| US60/909,580 | 2007-04-02 | ||
| US94856407P | 2007-07-09 | 2007-07-09 | |
| US60/948,564 | 2007-07-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501612A Division JP5221641B2 (ja) | 2007-04-02 | 2008-03-31 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013121353A JP2013121353A (ja) | 2013-06-20 |
| JP2013121353A5 true JP2013121353A5 (enExample) | 2014-05-22 |
| JP5840631B2 JP5840631B2 (ja) | 2016-01-06 |
Family
ID=39791007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501612A Expired - Fee Related JP5221641B2 (ja) | 2007-04-02 | 2008-03-31 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
| JP2013006880A Active JP5840631B2 (ja) | 2007-04-02 | 2013-01-18 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501612A Expired - Fee Related JP5221641B2 (ja) | 2007-04-02 | 2008-03-31 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US8263041B2 (enExample) |
| EP (2) | EP2653478B1 (enExample) |
| JP (2) | JP5221641B2 (enExample) |
| KR (1) | KR101515243B1 (enExample) |
| CN (2) | CN103275220B (enExample) |
| AU (1) | AU2008234615B2 (enExample) |
| BR (1) | BRPI0809989B8 (enExample) |
| CA (1) | CA2682851C (enExample) |
| EA (2) | EA018985B1 (enExample) |
| ES (2) | ES2609813T3 (enExample) |
| MX (1) | MX2009010639A (enExample) |
| WO (1) | WO2008120101A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2817005B2 (ja) | 1990-06-29 | 1998-10-27 | スズキ株式会社 | エンジン用オーバヒート検出装置 |
| EP2653478B1 (en) | 2007-04-02 | 2016-10-05 | Philogen S.p.A. | A novel antigen associated with the neovasculature of tumour metastases |
| KR101781638B1 (ko) * | 2007-07-25 | 2017-09-25 | 필로겐 에스.피.에이. | 종양 전이의 신생혈관과 관련된 피브리노겐의 ｅｄ-ａ 항원 |
| US10202442B2 (en) | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
| CN101918443B (zh) * | 2007-10-30 | 2013-07-17 | 菲洛根股份公司 | 一种与类风湿性关节炎相关的抗原 |
| EP2379116B1 (en) | 2009-01-07 | 2015-08-26 | Philogen S.p.A. | Antigens associated with endometriosis |
| EP2379117A2 (en) | 2009-01-07 | 2011-10-26 | Philogen S.p.A. | Cancer treatment |
| US8679488B2 (en) | 2009-08-05 | 2014-03-25 | Philogen S.P.A. | Targeting of bone marrow neovasculature |
| WO2011156639A1 (en) * | 2010-06-10 | 2011-12-15 | The Regents Of The University Of California | Eiiia and eiiib segments of fibronectin regulate stem cell fate |
| JP5548872B2 (ja) * | 2010-08-26 | 2014-07-16 | 株式会社島津製作所 | 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法 |
| EP2621535A1 (en) | 2010-09-29 | 2013-08-07 | Philogen S.p.A. | Thiazolidine linker for the conjugation of drugs to antibodies |
| EP2736535B1 (en) | 2011-07-27 | 2018-10-17 | Philogen S.p.A. | Il-12 immunoconjugate |
| ES2743423T3 (es) * | 2012-10-03 | 2020-02-19 | Philogen Spa | Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal |
| WO2015088348A1 (en) | 2013-12-12 | 2015-06-18 | Umc Utrecht Holding B.V. | Immunoglobulin-like molecules directed against fibronectin-eda |
| GB201507908D0 (en) | 2015-05-08 | 2015-06-24 | Philogen Spa | IL2 and TNF immunoconjugates |
| EP3322719B1 (en) | 2015-07-16 | 2019-12-18 | Philogen S.p.A. | Il22 immunoconjugates |
| HUE070615T2 (hu) | 2016-10-17 | 2025-06-28 | Pfizer | Anti-EDB antitestek és antitest-gyógyszer konjugátumok |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| CA3065153C (en) | 2017-06-07 | 2023-09-05 | Philogen S.P.A. | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
| EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
| CA3144533A1 (en) * | 2019-06-03 | 2020-12-10 | The University Of Chicago | Methods and compositions for treating cancer with cancer-targeted adjuvants |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| CR20220054A (es) | 2019-08-15 | 2022-06-06 | Janssen Biotech Inc | Materiales y métodos para fragmentos variables de cadena única mejorado |
| EP4185615A1 (en) | 2020-07-22 | 2023-05-31 | Philogen S.p.A. | Treatment of pulmonary hypertension |
| CN114350518B (zh) * | 2022-01-19 | 2023-01-13 | 广东乾晖生物科技有限公司 | 仿生肝微流控细胞培养-药物筛选芯片 |
| US20250197485A1 (en) | 2022-03-17 | 2025-06-19 | Universitätsklinikum Jena | Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension |
| WO2026003203A1 (en) | 2024-06-27 | 2026-01-02 | Philogen S.P.A. | Combination of an immunocytokine comprising targeted il2 and a jak inhibitor |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| US5420012A (en) | 1989-05-08 | 1995-05-30 | Locus Genex Oy | Method for the detection of reactive conditions |
| FI892197A7 (fi) * | 1989-05-08 | 1990-11-09 | Locus Oy | Foerfarande foer detektering av tumoerer. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0580859A4 (en) * | 1991-03-26 | 1994-09-14 | Otsuka Pharma Co Ltd | Anti-eda monoclonal antibody |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US5644033A (en) | 1992-12-22 | 1997-07-01 | Health Research, Inc. | Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment |
| DK1137941T4 (da) | 1998-12-10 | 2014-01-06 | Brystol Myers Squibb Company | Protein-scaffolds til antistof-mimetika og andre bindingsproteiner |
| ATE526039T1 (de) | 2000-02-24 | 2011-10-15 | Philogen Spa | Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
| CA2404919A1 (en) | 2000-04-06 | 2002-10-01 | Kyowa Hakko Kogyo Co. Ltd. | Diagnostic and therapeutic agents for rheumatoid arthritis |
| AU5867901A (en) | 2000-05-04 | 2001-11-12 | Philogen S.R.L. | Method for detecting tumors |
| EP1381629B1 (de) | 2000-09-07 | 2008-09-10 | Bayer Schering Pharma Aktiengesellschaft | REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II) |
| IT1317108B1 (it) | 2000-12-06 | 2003-05-26 | Philogen Srl | Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso. |
| EP1224943A1 (en) | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
| RU2352582C2 (ru) * | 2002-01-03 | 2009-04-20 | Шеринг Акциенгезельшафт | Конъюгаты, содержащие антитело, специфическое для ed-в-домена фибронектина, и их применение для обнаружения и лечения опухолей |
| WO2004000216A2 (en) | 2002-06-21 | 2003-12-31 | Duke University | Anti-tenascin antibody fragments and minibodies for treatment of lymphoma |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| WO2004094612A2 (en) | 2003-04-22 | 2004-11-04 | A & G Pharmaceutical, Inc. | Cancer specific monoclonal antibodies |
| WO2005009366A2 (en) | 2003-07-24 | 2005-02-03 | Cornell Research Foundation, Inc. | Restoring vascular function |
| US8038983B2 (en) | 2003-07-29 | 2011-10-18 | Immunomedics, Inc. | Fluorinated carbohydrate conjugates |
| CA2575675A1 (en) | 2004-07-30 | 2006-03-09 | Adeza Biomedical Corporation | Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| EA013537B1 (ru) | 2004-11-09 | 2010-06-30 | Филоген Спа | Антитела к тенасцину-с человека и их применение |
| ES2341126T3 (es) | 2005-05-11 | 2010-06-15 | Philogen S.P.A. | Proteina de fusion del anticuerpo l19 contra fibronectina ed-b e interleucina 12. |
| ES2606490T3 (es) | 2006-05-08 | 2017-03-24 | Philogen S.P.A. | Citocinas dirigidas por anticuerpos para terapia |
| EP2653478B1 (en) | 2007-04-02 | 2016-10-05 | Philogen S.p.A. | A novel antigen associated with the neovasculature of tumour metastases |
| KR101781638B1 (ko) * | 2007-07-25 | 2017-09-25 | 필로겐 에스.피.에이. | 종양 전이의 신생혈관과 관련된 피브리노겐의 ｅｄ-ａ 항원 |
| CN101918443B (zh) | 2007-10-30 | 2013-07-17 | 菲洛根股份公司 | 一种与类风湿性关节炎相关的抗原 |
| EP2379116B1 (en) * | 2009-01-07 | 2015-08-26 | Philogen S.p.A. | Antigens associated with endometriosis |
| EP2621535A1 (en) * | 2010-09-29 | 2013-08-07 | Philogen S.p.A. | Thiazolidine linker for the conjugation of drugs to antibodies |
| EP2736535B1 (en) * | 2011-07-27 | 2018-10-17 | Philogen S.p.A. | Il-12 immunoconjugate |
| WO2014174105A1 (en) * | 2013-04-25 | 2014-10-30 | Philochem Ag | Antibody-drug conjugates |
| WO2014173570A1 (en) * | 2013-04-26 | 2014-10-30 | Philogen S.P.A. | Il4 conjugated to antibodies against extracellular matrix components |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2008
- 2008-03-31 EP EP12195343.4A patent/EP2653478B1/en active Active
- 2008-03-31 JP JP2010501612A patent/JP5221641B2/ja not_active Expired - Fee Related
- 2008-03-31 ES ES12195343.4T patent/ES2609813T3/es active Active
- 2008-03-31 ES ES08737486T patent/ES2402171T3/es active Active
- 2008-03-31 EP EP08737486A patent/EP2142567B1/en not_active Not-in-force
- 2008-03-31 EA EA200970909A patent/EA018985B1/ru not_active IP Right Cessation
- 2008-03-31 WO PCT/IB2008/000965 patent/WO2008120101A2/en not_active Ceased
- 2008-03-31 CN CN201310167446.9A patent/CN103275220B/zh active Active
- 2008-03-31 CA CA2682851A patent/CA2682851C/en active Active
- 2008-03-31 KR KR1020097022770A patent/KR101515243B1/ko active Active
- 2008-03-31 EA EA201301224A patent/EA036322B1/ru not_active IP Right Cessation
- 2008-03-31 BR BRPI0809989A patent/BRPI0809989B8/pt not_active IP Right Cessation
- 2008-03-31 AU AU2008234615A patent/AU2008234615B2/en active Active
- 2008-03-31 US US12/593,872 patent/US8263041B2/en active Active
- 2008-03-31 CN CN2008800183109A patent/CN101687923B/zh active Active
- 2008-03-31 MX MX2009010639A patent/MX2009010639A/es active IP Right Grant
-
2012
- 2012-08-09 US US13/570,945 patent/US8481684B2/en active Active
-
2013
- 2013-01-18 JP JP2013006880A patent/JP5840631B2/ja active Active
- 2013-06-06 US US13/911,815 patent/US20130266511A1/en not_active Abandoned
- 2013-07-03 US US13/935,171 patent/US9181347B2/en active Active
-
2015
- 2015-10-05 US US14/874,923 patent/US9896503B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013121353A5 (enExample) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| IL299072A (en) | Antibodies and methods for using them | |
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| RU2013115891A (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| JP2011502137A5 (enExample) | ||
| JP2010523541A5 (enExample) | ||
| JP2021501744A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| JP2016135783A5 (enExample) | ||
| JP2017530092A5 (enExample) | ||
| JP2012034692A5 (enExample) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| NZ603529A (en) | Antibodies to human gdf8 | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| CO6331344A2 (es) | Anticuerpos aislados que unen a vegf, composiciones farmaceuticas que los comprenden y un portador farmaceuticamente aceptable y usos de los mismos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| HRP20201091T1 (hr) | Protutijela anti-axl | |
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| JP2020537520A5 (enExample) | ||
| JP2010534237A5 (enExample) |